Top

Osteoporosis International

Published in:

01-04-2013 | Original Article

Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan

Authors: M. A. Ward, Y. Xu, H. N. Viswanathan, B. S. Stolshek, B. Clay, J. L. Adams, J. D. Kallich, S. Fine, K. G. Saag

Published in: Osteoporosis International | Issue 4/2013

Abstract

Summary

We examined the association between osteoporosis treatment change and adherence, incident fractures, and healthcare costs among Medicare Advantage Prescription Drug (MAPD) plan members. Treatment change was associated with a small but significant increase in adherence, but was not associated with incident fracture or total healthcare costs. Overall adherence remained low.

Introduction

We examined the association between osteoporosis treatment change and adherence, incident fractures, and healthcare costs among MAPD plan members in a large US health plan.

Methods

We conducted a retrospective cohort study of MAPD plan members aged ≥50 years newly initiated on an osteoporosis medication between 1 January 2006 and 31 December 2008. Members were identified as having or not having an osteoporosis treatment change within 12 months after initiating osteoporosis medication. Logistic regression analyses and difference-in-difference (DID) generalized linear models were used to investigate the association between osteoporosis treatment change and (1) adherence to treatment, (2) incident fracture, and (3) healthcare costs at 12 and 24 months follow-up.

Results

Of the 33,823 members newly initiated on osteoporosis treatment, 3,573 (10.6 %) changed osteoporosis treatment within 12 months. After controlling for covariates, osteoporosis treatment change was associated with significantly higher odds of being adherent (medication possession ratio [MPR] ≥ 0.8) at 12 months (odds ratio [OR] = 1.18) and 24 months (OR = 1.13) follow-up. However, overall adherence remained low (MPR = 0.59 and 0.51 for the change cohort and MPR = 0.51 and 0.44 for the no-change cohort at 12 and 24 months, respectively). Osteoporosis treatment change was not significantly associated with incident fracture (OR = 1.00 at 12 months and OR = 0.98 at 24 months) or total direct healthcare costs (p > 0.4) in the DID analysis, but was associated with higher pharmacy costs (p < 0.004).

Conclusions

Osteoporosis treatment change was associated with a small but significant increase in adherence, but was not associated with incident fracture or total healthcare costs in the MAPD plan population. Overall adherence to therapy remained low.

Available only for authorised users

Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B (2002) Discontinuation of use and switching of antidepressants: influence of patient–physician communication. JAMA 288:1403–1409PubMedCrossRef

Wang Y, Alexander GC, Stafford RS (2007) Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 167:141–147PubMedCrossRef

Meissner B (2011) Switching of biologic disease-modifying antirheumatic drugs during the first year in patients with rheumatoid arthritis in a real-world setting. Arthritis and Rheumatism 63(Suppl 10):2197

Xu Y, Viswanathan HN, Ward MA, Clay B, Adams JL, Stolshek BS, Kallich JD, Fine S, Saag KG (2011) Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan. J Eval Clin Pract. doi:10.1111/j.1365-2753.2011.01766.x

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef

Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859–862PubMed

Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216PubMedCrossRef

Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013–1022PubMedCrossRef

10.

Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef

11.

Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905PubMedCrossRef

12.

Ryzner KL, Burkiewicz JS, Griffin BL, Komperda KE (2010) Survey of bisphosphonate regimen preferences in an urban community health center. Consult Pharm 25:671–675

13.

Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871–1886PubMedCrossRef

14.

Warriner AH, Patkar NM, Curtis JR, Delzell E, Gary L, Kilgore M, Saag K (2011) Which fractures are most attributable to osteoporosis? J Clin Epidemiol 64:46–53PubMedCrossRef

15.

McNemar Q (1947) Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153–157PubMedCrossRef

16.

Klabunde CN, Warren JL, Legler JM (2002) Assessing comorbidity using claims data: an overview. Medical care 40:IV-26–IV-35CrossRef

17.

Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH (2008) Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637–646PubMed

18.

Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619PubMedCrossRef

19.

Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460PubMedCrossRef

20.

Martin KE, Yu J, Campbell HE, Abarca J, White TJ (2011) Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm 17:596–609PubMed

21.

Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920PubMedCrossRef

Title: Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan
Authors: M. A. Ward
Y. Xu
H. N. Viswanathan
B. S. Stolshek
B. Clay
J. L. Adams
J. D. Kallich
S. Fine
K. G. Saag
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 4/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-2140-5

At a glance: The STEP trials

Springer Medicine

Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Quantitative vertebral morphometry based on parametric modeling of vertebral bodies in 3D

Hip fracture and other predictors of anti-osteoporosis drug use in Norway

Cold-activated brown adipose tissue is an independent predictor of higher bone mineral density in women

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study

No dose-dependent increase in fracture risk after long-term exposure to high doses of retinol or beta-carotene